Stevioside counteracts the glyburide-induced desensitization of the pancreatic beta-cell function in mice: studies in vitro

Metabolism: Clinical and Experimental

Volumn 55, Issue 12, 2006, Pages 1674-1680

  Chen, Jianguo ^a   Jeppesen, Per Bendix ^a   Nordentoft, Iver ^a   Hermansen, Kjeld ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; GLUCOSE TRANSPORTER 2; INSULIN; STEVIOSIDE;

ANIMAL CELL; ARTICLE; CELL FUNCTION; CELL ISOLATION; CONTROLLED STUDY; DESENSITIZATION; DOSE RESPONSE; DRUG EXPOSURE; DRUG MECHANISM; FEMALE; GENE EXPRESSION; HOMEOBOX; IN VITRO STUDY; INSULIN RELEASE; INSULIN RESPONSE; INSULIN SENSITIVITY; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; UPREGULATION;

ANIMALS; DIMETHYL SULFOXIDE; DITERPENES, KAURANE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE TRANSPORTER TYPE 2; GLUCOSIDES; GLYBURIDE; HOMEODOMAIN PROTEINS; HYPOGLYCEMIC AGENTS; INSULIN; ISLETS OF LANGERHANS; MICE; TRANS-ACTIVATORS;

EID: 34447518411     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2006.08.009     Document Type: Article

References (33)

1. Anonymous. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352 (1998) 854-865
2. Anonymous. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352 (1998) 837-853
3. Groop L.C. Sulfonylureas in NIDDM. Diabetes Care 15 (1992) 737-754
4. DeFronzo R.A., and Simonson D.C. Oral sulfonylurea agents suppress hepatic glucose production in non-insulin-dependent diabetic individuals. Diabetes Care 7 Suppl 1 (1984) 72-80
5. Duckworth W.C., Solomon S.S., Kitabchi A.E., et al. Effect of chronic sulfonylurea therapy on plasma insulin and proinsulin levels. J Clin Endocrinol Metab 35 (1972) 585-591
6. Fineberg S.E., and Schneider S.H. Glipizide versus tolbutamide, an open trial. Effects on insulin secretory patterns and glucose concentrations. Diabetologia 18 (1980) 49-54
7. Wajchenberg B.L., Nery M., Leme C.E., et al. Effect of prolonged glyclazide treatment on blood glucose and plasma insulin responses in obese patients with maturity-onset diabetes. Clin Pharmacol Ther 27 (1980) 375-378
8. Matthews D.R., Cull C.A., Stratton I.M., et al. UKPDS 26: sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group. Diabet Med 15 (1998) 297-303
9. 2+ regulation prevail over changes in insulin content. Br J Pharmacol 127 (1999) 1883-1891
10. Ball A.J., Flatt P.R., and McClenaghan N.H. Desensitization of sulphonylurea- and nutrient-induced insulin secretion following prolonged treatment with glibenclamide. Eur J Pharmacol 408 (2000) 327-333
11. Brissova M., Shiota M., Nicholson W.E., et al. Reduction in pancreatic transcription factor PDX-1 impairs glucose-stimulated insulin secretion. J Biol Chem 277 (2002) 11225-11232
12. Clocquet A.R., Egan J.M., Stoffers D.A., et al. Impaired insulin secretion and increased insulin sensitivity in familial maturity-onset diabetes of the young 4 (insulin promoter factor 1 gene). Diabetes 49 (2000) 1856-1864
13. Tiedge M., and Lenzen S. Effects of glucose refeeding and glibenclamide treatment on glucokinase and GLUT2 gene expression in pancreatic B-cells and liver from rats 1. Biochem J 308 Pt 1 (1995) 139-144
14. Chan P., Tomlinson B., Chen Y.J., et al. A double-blind placebo-controlled study of the effectiveness and tolerability of oral stevioside in human hypertension. Br J Clin Pharmacol 50 (2000) 215-220
15. Chan P., Xu D.Y., Liu J.C., et al. The effect of stevioside on blood pressure and plasma catecholamines in spontaneously hypertensive rats. Life Sci 63 (1998) 1679-1684
16. Gregersen S., Jeppesen P.B., Holst J.J., et al. Antihyperglycemic effects of stevioside in type 2 diabetic subjects. Metabolism 53 (2004) 73-76
17. Hong J., Chen L., Jeppesen P.B., et al. Stevioside counteracts the {alpha}-cell hypersecretion caused by long-term palmitate exposure. Am J Physiol Endocrinol Metab 290 (2006) E416-E422
18. Jeppesen P.B., Gregersen S., Rolfsen S.E., et al. Antihyperglycemic and blood pressure-reducing effects of stevioside in the diabetic Goto-Kakizaki rat. Metabolism 52 (2003) 372-378
19. +-channel activity. Metabolism 49 (2000) 208-214
20. Chen J., Jeppesen P.B., Abudula R., et al. Stevioside does not cause increased basal insulin secretion or beta-cell desensitization as does the sulphonylurea, glibenclamide: studies in vitro. Life Sci 78 (2006) 1748-1753
21. Lacy P.E., and Kostianovsky M. Method for the isolation of intact islets of Langerhans from the rat pancreas. Diabetes 16 (1967) 35-39
22. Gregersen S., Hermansen K., Yanaihara N., et al. Galanin fragments and analogues: effects on glucose-stimulated insulin secretion from isolated rat islets 1. Pancreas 6 (1991) 216-220
23. Jeppesen P.B., Gregersen S., Alstrup K.K., et al. Stevioside induces antihyperglycaemic, insulinotropic and glucagonostatic effects in vivo: studies in the diabetic Goto-Kakizaki (GK) rats. Phytomedicine 9 (2002) 9-14
24. Filipponi P., Marcelli M., Nicoletti I., et al. Suppressive effect of long term sulfonylurea treatment on A, B, and D cells of normal rat pancreas. Endocrinology 113 (1983) 1972-1979
25. Henquin J.C. Tolbutamide stimulation and inhibition of insulin release: studies of the underlying ionic mechanisms in isolated rat islets. Diabetologia 18 (1980) 151-160
26. Rabuazzo A.M., Buscema M., Vinci C., et al. Glyburide and tolbutamide induce desensitization of insulin release in rat pancreatic islets by different mechanisms. Endocrinology 131 (1992) 1815-1820
27. Ikegami H., Shima K., Tanaka A., et al. Interindividual variation in the absorption of glibenclamide in man. Acta Endocrinol (Copenh) 111 (1986) 528-532
28. Kawashima K., Kuzuya T., and Matsuda A. Radioimmunoassay of glibenclamide. Diabetes 28 (1979) 221-226
29. Del P.S., and Marchetti P. Beta- and alpha-cell dysfunction in type 2 diabetes. Horm Metab Res 36 (2004) 775-781
30. Rustenbeck I. Desensitization of insulin secretion. Biochem Pharmacol 63 (2002) 1921-1935
31. Bratanova-Tochkova T.K., Cheng H., Daniel S., et al. Triggering and augmentation mechanisms, granule pools, and biphasic insulin secretion. Diabetes 51 Suppl 1 (2002) S83-S90
32. Kemp D.M., and Habener J.F. Synergistic effect of dimethyl sulfoxide on glucagon-like peptide 1 (GLP-1)-stimulated insulin secretion and gene transcription in INS-1 cells: characterization and implications. Biochem Pharmacol 64 (2002) 689-697
33. Ahlgren U., Jonsson J., Jonsson L., et al. Beta-cell-specific inactivation of the mouse Ipf1/Pdx1 gene results in loss of the beta-cell phenotype and maturity onset diabetes. Genes Dev 12 (1998) 1763-1768